检索结果-南通市图书馆

Association between PTCH1 gene polymorphisms and chronic obstructive pulmonary disease susceptibility in a Chinese Han population:a case-control study

引用

Chinese medical Journal 2020年第17期133卷 2071-2077页

作者： Xi Kang Ting Guo Lyu Liu Shui-Zi Ding Cheng Lei Hong Luo department of Pulmonary and critical care medicine The Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China research Unit of respiratory Disease Central South UniversityChangshaHunan 410011China Diagnosis and Treatment center of respiratory Disease Central South UniversityChangshaHunan 410011China

Background:Chronic obstructive pulmonary disease(COPD)is a leading cause of morbidity and mortality ***-wide association studies in non-Asian population revealed a link between COPD and mutations in the PTCH1 gene encoding Patched1,a receptor in the Hedgehog signaling pathway important for lung morphogenesis and pulmonary *** aim of this study was to investigate the association between PTCH1 polymorphisms and the COPD risk in the Chinese Han ***:We performed a case-control study including 296 patients with COPD and 300 healthy ***-nucleotide polymorphisms in the PTCH1 gene were identified and genotyped based on the linkage disequilibrium analysis in all *** ratios(ORs)and 95%confidence intervals(95%CIs)were estimated using logistic regression analysis after adjustment for age,gender,and ***:In total,28 single-nucleotide polymorphisms were identified in patients with *** them,"A"allele of rs28491365(OR:1.388,95%CI:1.055-1.827,P=0.018),and"G"alleles of rs10512248(OR:1.299,95%CI:1.021-1.653,P=0.033)and rs28705285(OR:1.359,95%CI:1.024-1.803,P=0.033;respectively)were significantly associated with an increased COPD *** model analysis revealed that the"T/T"genotype of rs34695652 was associated with a decreased COPD risk under the recessive model(OR:0.490,95%CI:0.270-0.880,P=0.010),whereas rs28504650/rs10512248 haplotype CG was significantly associated with an increased COPD risk after adjustment for age,gender,and smoking status(OR:6.364,95%CI:1.220-33.292,P=0.028).Conclusions:The study provides a new insight into the role of PTCH1 polymorphisms in the susceptibility to COPD in the Chinese Han population.

关键词： PTCH1 Chronic obstructive pulmonary disease Gene polymorphism Case-control study Single-nucleotide polymorphisms

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expert consensus on clinical standardized application of high-flow nasal cannula oxygen therapy in adults

引用

Chinese medical Journal 2020年第11期133卷 1322-1324页

作者： Jian-Qiao Xu Long-Xiang Su Peng Yan Xing-Shuo Hu Ruo-Xuan Wen Kun Xiao Hong-Jun Gu Jin-Gen Xia Bing Sun Qing-Tao Zhou Yu-Chao Dong Jia-Lin Liu Pin-Hua Pan Hong Luo Qi Li Li-Qiang Song Si-Cheng Xu Yan-Ming Li Dao-Xin Wang Dan Li Qing-Yuan Zhan Li-Xin Xie 无 Departm ent of Pulmonary&critical care medicine Chinese People Liberation Army(PLA)General HospitalBeijing 100853China department of critical care medicine Peking Union Medical College HospitalBeijing 100005China department of Pulmonary&critical care medicine China and Japan Friendship HospitalBeijing 100029China department of Pulmonary&critical care medicine Beijing Chaoyang Hospital affiliated to Capital Medical UniversityBeijing 100020China department of Pulmonary&critical care medicine Peking University Third HospitalBeijing 100191China department of respiratory medicine Changhai HospitalShanghai 200433China department of respiratory medicine Ruijin Hospital Affiliated to the Shanghai Jiao Tong University Medical SchoolShanghai 200025China department of respiratory medicine XiangYa HospitalCentral South UniversityChangshaHunan 410008China department of Pulmonary&critical care medicine XiangYa Second Hospital of Central South UniversityChangshaHunan 410011China department of Pulmonary&critical care medicine Xinqiao Hospital of the Third Military Medical UniversityChongqing 400037China department of Pulmonary&critical care medicine Xijing Hospital of Fourth Military Medical UniversityXi'anShaanxi 710032China department of respiratory medicine The First Affiliated Hospital of Xinjiang Medical UniversityUrumqiXinjiang 830000China department of Pulmonary&critical care medicine Beijing HospitalBeijing 100730China department of respiratory medicine The Second Affiliated Hospital of Chongqing Medical UniversityChongqing 400010China department of respiratory medicine The First Bethune Hospital of Jilin UniversityChangchunJilin 130021China Pulmonary&critical care medicine Group of Chinese Thoracic Society/Pulmonary&critical care medicine Committee of Chinese Association of Chest Physician

High-flow nasal cannula oxygen therapy(HFNC)is a novel respiratory support technology and has been extensively applied in clinics in recent *** therapeutic equipment mainly includes an air-oxygen blender,an active humidifier,a high-flow nasal cannula,and a connecting inspiratory *** provides patients a humidified high-flow gas(8-80 L/min)with relatively stable oxygen concentration(21-100%),temperature(31-37℃)and performs oxygen therapy via a nasal cannula,which is very comfortable.

关键词： flow connecting high

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Effect of intradermal needle therapy at combined acupoints on patients’ gastrointestinal function following surgery for gastrointestinal tumors

引用

World Journal of clinical Cases 2022年第31期10卷 11427-11441页

作者： Min Guo Man Wang Lu-Lu Chen Fu-Juan Wei Jin-E Li Qing-Xiu Lu Li Zhang Hai-Xia Yang School of Nursing Xi'an Jiaotong University Health Science CenterXi'an 710061Shaanxi ProvinceChina School of medicine Zhejiang UniversityHangzhou 310016Zhejiang ProvinceChina department of geriatric Gastrosurgery The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an 710046Shaanxi ProvinceChina department of General Surgery The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an 710046Shaanxi ProvinceChina department of Traditional Chinese medicine The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an 710046Shaanxi ProvinceChina

BACKGROUND Postoperative gastrointestinal function recovery is critical for rapid rehabilitation of patients with gastrointestinal *** Chinese medicine offers considerable advantages for gastrointestinal disease ***,no study has reported the clinical efficacy of intradermal needle therapy(INT)at the Yuan-source,Luo-connecting,and He-sea points of the corresponding meridian for gastrointestinal function in patients following surgery for gastrointestinal *** To investigate the effect of INT at combined acupoints on patients’gastrointestinal function following surgery for gastrointestinal *** This randomized controlled trial was conducted at the second Affiliated Hospital of Xi’an Jiaotong University on patients with diagnosed gastrointestinal cancer,no distant metastases or organ failure,and hospitalized for elective radical tumor resection,who did not receive preoperative radiotherapy or *** were randomly allocated to either the intervention(n=32)or the control(n=32)*** in the control group received enhanced recovery care,while those in the intervention group received enhanced recovery care combined with INT at the Yuan-source,Luo-connecting,and He-sea *** surgery,INT was performed immediately upon the patient's return to the ward,and continued for seven consecutive *** independent samples t-test,chi-square test,and generalized estimating equations were used for data *** The participants’ages ranged from 40 to 80 years(average 63±10.1 years).Most participants underwent surgery for either gastric(43.8%)or colon cancer(39.1%)and had adenocarcinoma(87.5%).Significant differences were noted in time to first postoperative flatus passage(66±27 h vs 103±41 h,P<0.001),time to first defecation(106±44 h vs 153±50 h,P<0.001),and time to first oral feeding(73±30 h vs 115±38 h,P<0.001)between the intervention and control *** symptoms,including abdomin

关键词： Acupuncture Acupuncture points Gastric tumors Traditional Chinese medicine Postoperative care

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome

引用

Chinese medical Journal 2019年第22期132卷 2670-2676页

作者： Li-Da Chen Jie-Feng Huang Qing-Shi Chen Guo-Fu Lin Hui-Xue Zeng Xiao-Fen Lin Xue-Jun Lin Li Lin Qi-Chang Lin department of respiratory and critical care medicine Zhangzhou Affiliated Hospital of Fujian Medical UniversityZhangzhouFujian 363000China department of respiratory and critical care medicine The First Affiliated Hospital of Fujian Medical UniversityFuzhouFujian 350005China 'Fujian Provincial Sleep-disordered Breathing Clinic center FuzhouFujian 350005China The second Affiliated Hospital of Fujian medical University QuanzhouFujian 362000China department of Cadre Ward Zhangzhou Affiliated Hospital of Fujian Medical UniversityZhangzhouFujian 363000China department of Laboratory medicine Zhangzhou Affiliated Hospital of Fujian Medical UniversityZhangzhouFujian 363000China

Background:Obstructive sleep apnea hypopnea syndrome(OSAHS)is a contributing factor for non-alcoholic fatty liver di:(NAFLD).Non-invasive algorithms including fatty liver index(FLI)and hepatic steatosis index(HSI)have been used as a screening test for NAFLD in epidemiologic *** aim of this study is to compare the diagnostic accuracy of FLI and HSI for NAFLD detection in adults with ***:We enrolled consecutive adult subjects who were newly diagnosed with OSAHS from March 2016 to January *** was diagnosed by *** accuracy and cut-off point of the FLI and HSI to detect NAFLD were assessed by analyzing the area under the receiver operating characteristic(AUROC)curve and the maximum Youden index analysis,***:The 326 subjects were diagnosed as NAFLD according to ultrasound findings,while 105 subjects who had normal abdominal ultrasonography were grouped as *** FLI and HSI values were significantly higher in patients with NAFLD compared with *** AUROC of FLI and HSI for predicting NAFLD was 0.802(95%confidence interval[CI]0.762-0.839)and 0.753(95%CI 0.710-0.793),*** AUROC of FLI was significantly higher than that of HSI(P=0.0383).The optimal cut-off value of FLI and HSI was 60(sensitivity 66%and specificity 80%)and 35(sensitivity 81%and specificity 60%),***:Both FLI and HSI can serve as screening tools for NAFLD in OSAHS *** FLI shows better performance in diagnosing NAFLD than HSI.

关键词： Obstructive sleep apnea hypopnea syndrome Fatty liver index Hepatic steatosis index Non-alcoholic fatty liver disease

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity

引用

Signal Transduction and Targeted Therapy 2021年第8期6卷 2472-2483页

作者： Lin Gao Shanze Chen Malin Hong Wenbin Zhou Bilan Wang Junying Qiu Jinquan Xia Pan Zhao Li Fu Jigang Wang Yong Dai Ni Xie Qinhe Yang Hsien-Da Huang Xiang Gao Chang Zou department of clinical medical research center The Second Clinical Medical CollegeJinan University(Shenzhen Peopled Hospital)The First Affiliated Hospital of Southern University of Science and TechnologyShenzhenGuangdongPR China Integrated Chinese and Western medicine Postdoctoral research Station Jinan UniversityGuangzhouGuangdongPR China department of respiratory and critical care medicine First Affiliated Hospital of Southern University of Science and TechnologyThe Second Clinical Medical CollegeJinan University(Shenzhen Peopled Hospital)Shenzhen Institute of Respiratory DiseasesShenzhenGuangdongPR China Shenzhen Public Service Platform on Tumor Precision medicine and Molecular Diagnosis the Second Clinical Medical CollegeJinan University(Shenzhen People's Hospital)ShenzhenGuangdongPR China department of Pharmacy West China Second University Hospital of Sichuan UniversityChengduPR China Guangdong Provincial Key Laboratory of Regional Immunity and diseases Department of Pharmacology and International Cancer CenterShenzhen University Health Science CenterShenzhenGuangdongChina department of Integrated Chinese and Western medicine Jinan UniversityGuangzhouGuangdongPR China School of Life and Health Sciences The Chinese University of Kong HongShenzhenChina Warshel Institute for Computational Biology The Chinese University of HongKongShenzhenChina department of Neurosurgery State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengduPR China

Triple-negative breast cancer(TNBC)is the most challenging subtype of breast *** endeavor has been made to explore the molecular biology basis of ***,we reported a novel function of factor Kinectin 1(KTN1)as a carcinogenic promoter in ***1 expression in TNBC was increased compared with adjacent tissues or luminal or Her2 subtypes of breast cancer,and TNBC patients with high KTN1 expression have poor *** functional studies,knockdown of KTN1 inhibited the proliferation and invasiveness of TNBC both in vitro and in vivo,while overexpression of KTN1 promoted cancer cell proliferation and ***-seq analysis revealed that the interaction of cytokine-cytokine receptor,particularly CXCL8 gene,was upregulated by KTN1,which was supported by the further ***8 depletion inhibited the tumorigenesis and progression of ***,rescue experiments validated that KTN1-mediated cell growth acceleration in TNBC was dependent on CXCL8 both in vitro and in ***,it was found that KTN1 enhanced the phosphorylation of NF-κB/p65 protein at Ser536 site,and specifically bound to NF-κB/p65 protein in the nucleus and cytoplasm of ***,the transcription of CXCL8 gene was directly upregulated by the complex of KTN1 and NF-κB/p65 *** together,our results elucidated a novel mechanism of KTN1 gene in TNBC tumorigenesis and ***1 may be a potential molecular target for the development of TNBC treatment.

关键词： inhibited breast cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)

引用

Cancer Communications 2022年第12期42卷 1314-1330页

作者： Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun department of medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingP.R.China department II of Thoracic medicine Hunan Cancer HospitalChangshaHunanP.R.China department of medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China department of respiratory diseases The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiangP.R.China The Third department of Chemotherapy Weihai Municipal HospitalWeihaiShandongP.R.China department of medical Oncology Linyi Cancer HospitalLinyiShandongP.R.China Oncology department General Hospital of Chinese People’s Liberation ArmyBeijingP.R.China department of Chest medicine Beijing Cancer HospitalBeijingP.R.China department of Oncology Beijing Chao-Yang HospitalCapital Medical UniversityBeijingP.R.China department of medical Oncology Sir Run Run Shaw HospitalZhejiang UniversityHangzhouZhejiangP.R.China department of medical Oncology Xuzhou Central HospitalXuzhou Medical UniversityXuzhouJiangsuP.R.China department of medical Oncology Shanghai Pulmonary HospitalTongji UniversityShanghaiP.R.China department of Lung Cancer Tianjin Medical University Cancer Institute and HospitalTianjinP.R.China department of medical Oncology Cancer HospitalThe First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityThe Third Clinical Medical CollegeFujian Medical UniversityXiamenFujianP.R.China department of medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China department of Oncology Affiliated Hospital of Jining Medical UniversityJiningShandongP.R.China department of respiratory and critical care medicine Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijingP.R.China department of medical Oncology Key L

Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are *** study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic ***:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based *** were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance *** primary endpoint was overall survival(OS)in the full analysis set(FAS).secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and ***:Between August 25,2017,and November 7,2018,290 patients were *** FAS,10 patients fromthe docetaxel armwere *** OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel *** median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel *** biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatme

关键词： Non-small cell lung cancer Carcinoma squamous cell Sintilimab Immunotherapy Survival Randomized controlled trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

引用

Frontiers of medicine 2021年第3期15卷 486-494页

作者： Dongsheng Wang Binqing Fu Zhen Peng Dongliang Yang Mingfeng Han Min Li Yun Yang Tianjun Yang Liangye Sun Wei Li Wei Shi Xin Yao Yan Ma Fei Xu Xiaojing Wang Jun Chen Daqing Xia Yubei Sun Lin Dong Jumei Wang Xiaoyu Zhu Min Zhang Yonggang Zhou Aijun Pan Xiaowen Hu Xiaodong Mei Haiming Wei Xiaoling Xu department of Pulmonary and critical care medicine the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)Hefei 230001China Division of Life Sciences and medicine University of Science and Technology of ChinaHefei 230027China Intensive care Unit the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)Hefei 230001China Drug clinical Trail Institution the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)Division of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001China department of Infectious diseases Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430000China department of respiratory medicine the Second People’s Hospital of FuyangFuyang 236000China department of respiratory medicine National Key Clinical SpecialtyBranch of National Clinical Research Center for Respiratory DiseaseXiangya HospitalCentral South UniversityXiangya Lung Cancer CenterXiangya HospitalCentral South UniversityHunan Provincial Clinical Research Center for Respiratory DiseasesChangsha 410000China Lu’an People’s Hospital Affiliated to Anhui medical University Lu’an 237005China department of Pulmonary and critical care medicine the First Affiliated Hospital of Bengbu Medical CollegeClinical Research Center for Respiratory Disease(tumor)in Anhui ProvinceBengbu 233004China department of respiratory medicine Anqing Hospital Affiliated to Anhui Medical UniversityAnqing 246000China The First Affiliated Hospital of Nanjing medical University Nanjing 210000China department of Rheumatology and Immunology the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)Hefei 230001China department of Oncology the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)Hefei 230001China department of Endocrinology

Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 *** attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this *** conducted a randomized,controlled,open-label multicenter trial among COVID-19 *** patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care *** cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were ***-three patients were randomized to the tocilizumab group,and 32 patients to the control *** cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events *** mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes *** patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome.

关键词： tocilizumab coronavirus disease 2019(COVID-19) cytokine storm

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Ensemble learning system to identify nutritional risk and malnutrition in cancer patients without weight loss information

引用

Science China(Life Sciences) 2023年第5期66卷 1200-1203页

作者： Liangyu Yin Jie Liu Ming Liu Jin Zheng Aiguo Xu Quanjun Lyu Yongdong Feng Zengqing Guo Hu Ma Jipeng Li Zhikang Chen Hui Wang Zengning Li Chunling Zhou Xi Gao Min Weng Qinghua Yao Wei Li Tao Li Hanping Shi Hongxia Xu department of clinical Nutrition Daping HospitalArmy Medical University(Third Military Medical University)Chongqing 400042China Institute of Hepatopancreatobiliary Surgery Southwest HospitalArmy Medical University(Third Military Medical University)Chongqing 400038China department of General Surgery The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086China department of Traditional Chinese medicine Tangdu HospitalAir Force Medical University(The Fourth Military Medical University)Xi’an 710038China department of respiratory and critical care medicine The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of Nutrition The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of GI Cancer research Institute Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China department of medical Oncology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhou 350014China department of Oncology The Affiliated Hospital of Zunyi Medical UniversityZunyi 563000China department of Experimental Surgery Xijing HospitalFourth Military Medical UniversityXi’an 710032China department of Colorectal and Anus Surgery Xiangya Hospital of Central South UniversityChangsha 410008China department of Oncology The People’s Hospital of DujiangyanDujiangyan 611830China department of clinical Nutrition The First Hospital of Hebei Medical UniversityShijiazhuang 050031China department of clinical Nutrition The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin 150001China department of Oncology Affiliated Hospital of North Sichuan Medical CollegeNanchong 637000China department of clinical Nutrition The First Affiliated Hospital of Kunming Medical UniversityKunming 650032China department of Integrated Chinese and Western medicine Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)Hangzhou 310022China Cancer center The First Hospital

Dear Editor,Malnutrition is a prevalent disease in oncology practice(Arends et al.,2017).With its cancer-specific prevalence ranging from 21%–72%,malnutrition is responsible for 10%–20% cancer deaths(Yin et al.,2021b).However,malnutrition is often underestimated,misclassified,or left untreated in cancer care(Hébuterne et al.,2014).

关键词： malnutrition cancer

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Risk factors for disease severity in COVID-19 patients: A single-center retrospective study

引用

Journal of Intensive medicine 2021年第2期1卷 117-122页

作者： Jingqing Xu Yanping Cai Min Li Qing Li Yingrui Zhang Ying Jiang Wanli Yan Xuemei Chen Hongxuan Zhang Zhaonan Zeng Fayang Lian Xiuling Shang Rongguo Yu department of critical care medicine Fujian Provincial HospitalFujian Provincial Clinical Teaching Hospital Affiliated to the Fujian Medical UniversityFujian Provincial Center for Critical Care MedicineFuzhouFujian 350000China Infection Division Wuhan Jinyintan HospitalWuhanHubei 430000China department of critical care medicine The Second Affiliated People’s Hospital of Fujian University of Traditional Chinese MedicineFuzhouFujian 350000China center for Experimental research in clinical medicine Fujian Provincial HospitalFuzhouFujian 350000China department of research Fujian Provincial HospitalFuzhouFujian 350000China

Background:The outbreak of coronavirus disease 2019(COVID-19)has posed a huge threat to human ***,little is known regarding the risk factors associated with COVID-19 *** aimed to explore early-stage disease risk factors associated with eventual disease ***:This study enrolled 486 hospitalized,non-intensive care unit(ICU)-admitted adult patients with COVID-19(age≥18 years)treated at Wuhan Jinyintan Hospital,who were divided into three groups according to disease *** demographic,clinical,and laboratory data at admission and clinical outcomes were compared among severity groups,and the risk factors for disease severity were identified by multiple regression ***:Of 486 patients with COVID-19,405(83.33%)were discharged,33(6.71%)died outside of the ICU,and 48(7.20%)were still being treated in the ICU by the time the study period *** differences in age,lymphocyte counts,and the levels of procalcitonin,aspartate aminotransferase,and D-dimer(Prespiratory syndrome coronavirus 2(SARS-CoV-2)may impair the immune system,the blood coagulation system,and hepatic and cardiac *** clinical characteristics and laboratory findings can help identify patients with a high risk of disease severity,which can be significant for appropriate resource allocation during the COVID-19 pandemic.

关键词： COVID-19 Disease progression Risk factor Decreased lymphocytes Procalcitonin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunotherapy in non-small cell lung cancer:rationale,recent advances and future perspectives

引用

Precision clinical medicine 2021年第4期4卷 258-270页

作者： Wenxin Luo Zhoufeng Wang Ting Zhang Lan Yang Jinghong Xian Yalun Li Weimin Li department of respiratory and critical care medicine West China HospitalSichuan UniversityChengdu 610041China Precision medicine research center West China HospitalSichuan UniversityChengdu 610041China clinical medical College and the First Affiliated Hospital of Chengdu medical College Chengdu 610500China department of clinical research Management West China HospitalSichuan UniversityChengdu 610041China

Lung cancer,with non-small cell lung cancer(NSCLC)being the major type,is the second most commonmalignancy and the leading cause of cancer-related death ***,represented by immune checkpoint inhibitors(ICIs),has been one of the greatest advances in recent years for the treatment of solid tumors including ***,not all NSCLC patients experience an effective response to immunotherapy with the established selection criteria of programmed death ligand 1(PD-L1)and tumor mutational burden(TMB).Furthermore,a considerable proportion of patients experience unconventional responses,including pseudoprogression or hyperprogressive disease(HPD),immune-related toxicities,and primary or acquired resistance during the immunotherapy *** better understand the immune response in NSCLC and provide reference for clinical decision-making,we herein review the rationale and recent advances in using immunotherapy to treat ***,we discuss the current challenges and future strategies of this approach to improve its efficacy and safety in treating NSCLC.

关键词： non-small cell lung cancer immunotherapy immune checkpoint inhibitors adoptive cell therapy vaccine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：